BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk Stock Rises on Positive Ozempic Trial Results
Novo Nordisk Stock Rises on Positive Ozempic Trial Results
8
1
BTCCSquare news:
Novo Nordisk shares gained 2.1% following a Financial Times report highlighting improved weight loss outcomes with higher semaglutide doses. Patients taking 7.2mg of Ozempic's active ingredient achieved 19% weight reduction over 72 weeks, outperforming the standard 2.4mg regimen's 16% result.
While Eli Lilly's tirzepatide shows marginally better efficacy at maximum doses, Novo's competitive pricing strategy could strengthen Ozempic's market position. The stock trades at a significant discount to Lilly—14 times earnings versus 49—while offering a 3.1% dividend yield against Lilly's 0.8%.
By:
